{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-192827","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.429498+00:00","generated_at":"2026-06-13T03:19:01.682431+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA approves Tarsus' XDEMVY (lotilaner) 0.25% for Demodex blepharitis","bullets":["FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for treatment of Demodex blepharitis.","Approval announced July 25, 2023 via press release and investor webcast.","Corporate presentation and webcast replay posted on Tarsus' investor website."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-192827","json":"https://secwatch.observer/filing/0001193125-23-192827.json","markdown":"https://secwatch.observer/filing/0001193125-23-192827.md","text":"https://secwatch.observer/filing/0001193125-23-192827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000119312523192827/0001193125-23-192827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000119312523192827/d540952d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:19:01.682431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}